Miguel Sieler Head Of Neovasc Inc. (NVC): "We Develop A Groundbreaking Technology"
6/19/2014 10:30:01 AM
PARIS, June 19, 2014 (GLOBE NEWSWIRE) -- Neovacs, (Alternext Paris: ALNEV), is a leader in active immunotherapies for the treatment of autoimmune diseases. The company will participate to the first annual "French Life Sciences Days", a major event that will bring together French biotech and medtech companies listed on the NYSE Euronext exchange, on 25 & 26 June, with members of the French and North American financial community. In this TV interview, Miguel Sieler Neovacs CEO explained the strategy of the company for US investors.
Help employers find you! Check out all the jobs and post your resume.
comments powered by